Unknown

Dataset Information

0

A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates.


ABSTRACT: Adeno-associated virus (AAV) has provided the gene therapy field with the most powerful in vivo gene delivery vector to realize safe, efficacious, and sustainable therapeutic gene expression. Because many clinically relevant properties of AAV-based vectors are governed by the capsid, much research effort has been devoted to the development of AAV capsids for desired features. Here, we combine AAV capsid discovery from nature and rational engineering to report an AAV9 capsid variant, designated as AAV9.HR, which retains AAV9's capability to traverse the blood-brain barrier and transduce neurons. This variant shows reduced transduction in peripheral tissues when delivered through intravascular (IV) injection into neonatal mice. Therefore, when IV AAV delivery is used to treat CNS diseases, AAV9.HR has the advantage of mitigating potential off-target effects in peripheral tissues compared to AAV9. We also demonstrate that AAV9.HR is suitable for peripheral tissue-detargeted CNS-directed gene therapy in a mouse model of a fatal pediatric leukodystrophy. In light of recent success with profiling diversified natural AAV capsid repertoires and the understanding of AAV capsid sequence-structure-function relationship, such a combinatory approach to AAV capsid development is expected to further improve vector targeting and expand the vector toolbox for therapeutic gene delivery.

SUBMITTER: Wang D 

PROVIDER: S-EPMC5948233 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates.

Wang Dan D   Li Shaoyong S   Gessler Dominic J DJ   Xie Jun J   Zhong Li L   Li Jia J   Tran Karen K   Van Vliet Kim K   Ren Lingzhi L   Su Qin Q   He Ran R   Goetzmann Jason E JE   Flotte Terence R TR   Agbandje-McKenna Mavis M   Gao Guangping G  

Molecular therapy. Methods & clinical development 20180316


Adeno-associated virus (AAV) has provided the gene therapy field with the most powerful <i>in vivo</i> gene delivery vector to realize safe, efficacious, and sustainable therapeutic gene expression. Because many clinically relevant properties of AAV-based vectors are governed by the capsid, much research effort has been devoted to the development of AAV capsids for desired features. Here, we combine AAV capsid discovery from nature and rational engineering to report an AAV9 capsid variant, desig  ...[more]

Similar Datasets

| S-EPMC5503098 | biostudies-literature
| S-EPMC5532583 | biostudies-other
| S-EPMC4492398 | biostudies-literature
| S-EPMC4714946 | biostudies-literature
| S-EPMC2396676 | biostudies-literature
| S-EPMC6667477 | biostudies-literature
| S-EPMC9840684 | biostudies-literature
| S-EPMC7994635 | biostudies-literature
| S-EPMC5063516 | biostudies-other
| S-EPMC4554683 | biostudies-literature